Beginning January 1, 2019, Blue Cross and Blue Shield Federal Employee Program (FEP®) benefit procedures will change for the autoimmune infusion drug infliximab (brand names Remicade, Inflectra, and Renflexis). Members currently receiving the drug may be covered under either pharmacy or medical benefits. However, members who receive a first infusion on or after January 1, 2019 can only receive the drug under medical benefits. Members who receive it under pharmacy benefits prior to January 1, 2019 will continue receiving it under pharmacy benefits.

 

If you have any questions please contact FEP Customer Service at 800-852-3316.



Featured In:
December 2018 Anthem New Hampshire Provider Newsletter